یپوفارم Biopharm

The 5th Biopharm Scientific Annual Meeting BSAM5, Alger le 28 juin 2025



ABBAS Nacira^{1*}, BOUAMEUR Sarah¹, DADOUCH Meriem^{2,3}, BENYETTOU Imène⁴, MOUSSAOUI KHEDAM Nassima¹,

¹Laboratory of Galenic Pharmacy, Faculty of Medicine, Oran -1, Algeria,

² Research Laboratory of Physical Chemistry of Macromolecules and Biological Interfaces,

⁴Hygiene Laboratory of Oran, Algeria.

³ Department of pharmacy, Faculty of Medicine, University of Sidi Bel Abbes, Algeria.

Abstract

* E-mail: abbasnacira07@gmail.com

Objective: This study aims to develop and characterize lipidic vesicles highly loaded with ciprofloxacin hydrochloride (CPX-HCL) obtained by ethanol injection method.

Materials and Methods: Six formulations of liposomes were developed by the ethanol injection technique. Lipoid S75 was utilized at concentrations ranging from 40 to 100 mg/ml, while cholesterol was incorporated at concentrations between 10 and 15 mg/ml. CPX-HCl concentration was maintained at 3.5 mg/ml across all formulations. The process was conducted at 50°C, with an injection flow rate of 0.6 ml/min. Each formulation was characterised based on these parameters: encapsulation efficiency (EE), particle size, particle distribution index, pH, morphology and physical stability. A microbiological efficacy test was conducted on reference strains of pseudomonas aeruginosa. Stability studies (Ph and EE) conducted at 10°C, abated from light.

Results: Dynamic Light Scattering analysis of liposomal suspension revealed different particle sizes ranging from 229.2 nm to 797.8 nm, and varying polydispersity indexes from 0.471 to 0.967 (in terms of light intensity). Among all formulations, F3 presented the best granulometric results and the smallest mean diameter. Conversely, F4 exhibited the largest vesicle diameter (797.8 nm). The EE varied from 39.01% (F6) to 97.56% (F4). The microscopic analysis showed unilamelar vesicles for all formulations. According to liposome classification, F3 corresponds to Small Unilamellar Vesicles (SUVs), whereas F4 aligns with the Large Unilamellar Vesicles (LUVs). Formulations pH values varied from 6.5 to 5.5.

After 14 days, F4 showed unchanged characteristics. Unfortunately, F3 exhibited a reduction in EE percentage to below 5%. When compared to free CPX-HCl solution, microbiological assays revealed that both F3 and F4 enhanced the CPX antibacterial activity against Pseudomonas aeruginosa, as evidenced by the largest inhibition zones. In the same conditions, the corresponding placebos didn't express any antibacterial effect.

Conclusion: This study emphasizes the potential of liposomes as effective carriers for Ciprofloxacin nanoencapsulation, significantly improving its antibacterial efficacy, and suggests that Ciprofloxacin-liposomes could provide a promising approach for the management of infections affecting ocular, cutaneous, and respiratory pathways.

Keywords: Drug delivery, ethanol injection, liposomes, pseudomonas aeruginosa, vesicles.

INTRODUCTION Ciprofloxacin hydrochloride (CPX-HCl) is an Liposomal formulations of CPX-HCl present an effective drug for treatment of infectious innovative strategy to enhance drug delivery, diseases; however, its clinical efficacy is improve stability, and mitigate toxicity (2). hindered by low bioavailability across various Objective administration routes. ✤ This study aims to develop and characterise lipid The need for frequent dosing to achieve vesicles with a high efficacy of encapsulation therapeutic levels can lead to patient non-(EE) for CPX-HCl. compliance and potential side effects (1, 2).

ͺͺϒͿϪͲϾϓϪͳ AND METHOD Table 1. Liposomal formulae composition

lipid





and enhanced EE (3). effective encapsulation of CPX, physical stability over 30 Incorporating cholesterol significantly days at 10°C, suggesting a consistent with previous increases liposome diameter by disrupting the correlation between vesicle studies solid on phospholipid bilayer, enhancing membrane size and structural integrity microparticles (SLM) of CPXfluidity, and promoting uniform aqueous phase during storage. HCL(5). distribution(4). REFERENCES A-CONCLUSTON -

	1.Khan MK, Khan MF, Khan H, Mustafa G. Bioavailability of ciprofloxacin tablets in humans and
This study illustratos the officiency of linesemes as	its correlation with the dissolution rates. Pak J Pharm Sci. $2009; 22(3):329-34.$
THIS Study IIIUSTIALES the efficacy of Tiposomes as	2. Nagarsenker MS, Londhe VY . Preparation and evaluation of liposomal formulations of
carriers for ciproflovacin nanoencansulation	tropicamide for ocular delivery. International journal of pharmaceutics. 1999.
	3.Wen-xiao S. Preparation and Particle Size Controlling of Papain Nano-Liposomes. Journal of
significantly enhancing its antibacterial notency and	Shanghai Jiaotong University, 2007
significancity childhering its ancibacterial potency and	4.Briuglia ML, Rotella C, Dimitrios AL. Influence of cholesterol on liposome stability and on
indicating their potential application in treating	in vitro drug release.2024
indicating their potential apprication in treating	5. Abbas N, Bouameur S, Moussaoui Khedam N. Preparation and characterization of lipidic
ocular, cutaneous, and respiratory infections.	microparticles of ciprofloxacin hydrochloride. 4 th Biopharm Scientific Annual Meeting (BSAM
coarar, cacanecas, and respiratory informations.	4); 2024; Algeria